Department of Cardiology, All India Institute of Medical Sciences, India
Research Article
Bosentan, Ambrisentan, and Macitentan: Practical Therapeutics
Author(s): Sivasubramanian Ramakrishnan*, Sataroopa Mishra and Saurabh Kumar Gupta
Endothelin receptor blockers are the mainstay of treatment for pulmonary arterial hypertension. These drugs produce pulmonary vasodilation and reduce smooth muscle proliferation by blocking endothelin receptors on pulmonary vascular smooth muscles. Bosentan is the most studied and most widely used endothelin receptor blocker. It is the only drug of this class which is approved for use in children. Nonetheless, better side effect profile and cost effectivity has prompted many to prefer ambrisentan and macitentan over bosentan. This review focuses on the practical aspects of bosentan, ambrisentan and macitentan therapeutics. .. View more»